300244 迪安诊断
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,936,485-20.61%12,196,22413,408,32020,282,46913,082,613
减:营业总成本4,643,503-18.82%11,403,54612,243,28216,603,82111,084,409
    其中:营业成本3,574,366-20.50%8,779,6079,213,38312,745,8118,076,949
               财务费用70,037-29.12%198,032220,608298,236217,479
               资产减值损失(170)-93.54%(401,579)(16,738)(624,025)(272,189)
公允价值变动收益7,354-145.53%(12,697)(727)(56,236)83,354
投资收益10,703115.56%38,713(17,596)48,78755,338
    其中:对联营企业和合营企业的投资收益3,7466.70%11,584(6,722)26,76339,785
营业利润115,853-53.26%(31,115)842,1832,822,6091,837,935
利润总额110,800-55.04%(51,826)798,3262,543,5621,790,997
减:所得税费用28,597-61.25%117,407216,735681,092307,396
净利润82,203-52.38%(169,233)581,5911,862,4701,483,601
减:非控股权益71,926-28.71%188,045274,130428,279320,717
股东净利润10,277-85.68%(357,278)307,4611,434,1911,162,884

市场价值指针
每股收益 (元) *0.017-85.43%-0.5790.4922.3021.874
每股派息 (元) *----0.9000.0600.2000.135
每股净资产 (元) *10.278-13.27%10.50312.06911.8819.416
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容